Pfizer Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).
Zoetis Inc. and Nexvet Biopharma plc announced an agreement. Zoetis, through a wholly owned subsidiary (Zoetis Bidco), will purchase Nexvet, an innovator in monoclonal antibody therapies for companion animals, for a purchase price of US$6.72 per share, representing an aggregate equity valuation of approximately $85 million.
Regular use of pain relievers over many years may increase the risk of hearing loss, a recent study suggests.
Indianapolis-based Eli Lilly and Company is on a roll, announcing that between 2014 and 2023, it may launch 20 new products.
DURECT announced its licensee, Pain Therapeutics, has resubmitted the New Drug Application for REMOXY (oxycodone capsules CII) to the U.S. Food and Drug Administration.
BioDelivery Sciences International Inc said the U.S. Food and Drug Administration had approved its opioid treatment for chronic pain, sending the drugmaker’s shares up 19 percent in premarket trading on Monday. Endo International Plc licensed the worldwide manufacturing and marketing rights to the treatment, Belbuca, from BioDelivery in 2012. Belbuca is an opioid film patch […]
CANTON, Mass. – Collegium Pharmaceutical, Inc. ’s (COLL) stock is down nearly 10 percent in aftermarket trading after the company announced the U.S. Food and Drug Administration will not complete a review of the company’s extended-release opioid pain medication drug Xtampza. Michael Heffernan, Collegium’s chairman and chief executive officer, said the company remains confident […]